Shots:

• Cipla has priced its generic version of remdesivir- Cipremi at Rs 4000 ($53.34/ 100ml) vial- making it the lowest priced COVID-19 therapy across the globe- when compared with Hetero’s Covifor which is sold at Rs 5-400/ 100 mg vial and Mylan’s Desrem is priced at Rs 4-800.
• The company focuses on supplying over 80-000 vials within the first month. To ensure equitable distribution- Cipremi will be available via government and hospital channels 
• On Jul 07- 2020- Sovereign Pharma- which is manufacturing and packaging the therapy for Cipla had dispatched the first batch. Gilead has priced the original version at $390/ 100 mg vial for developed countries while signed a license agreement with generic producers to make the treatment widely available

Click here to read full press release/ article | Ref: Reuters | Image: Express Pharma

Related News: Cipla Launches Cipremi (remdesivir lyophilized powder for injection 100 mg) to Treat Patients with Severe COVID-19